CNA Database

Disease Name	MESH header	Disease Id	Prognosis	Gene Name	Band	Cytogenetic Aberration	Non-cytogenetic Characteristic	Gene Entrez ID	Cytoband	Aberration	Aberration Label	Described Effect	Bearing	Therapy Type	Therapy Name	Therapy Class	Therapy Id	Diagnostic, Prognostic, Therapy related	pubmed ids
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		MET	7q31.2	Amplification		4233	7q31.2	Gain	MET Amplification	Targeted Therapies May Be Available (i.e. Crizotinib)	pos	drug	Crizotinib			Therapy	PMID 21716144 PMID 26628860
Gastrointestinal Stromal Tumors	Gastrointestinal Stromal Tumors	D046152		KIT	4q12	Amplification		3815	4q12	Gain	KIT Amplification	Targeted Therapies May Be Available (i.e. Tyrosine Kinase Inhibitors); Recurring in Gastrointestinal Stromal Tumor; Imatinib Mylate Treatment	pos	drug	Imatinib Mesylate			Therapy	26098203
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		CRKL	22q11.21	Amplification		1399	22q11.21	Gain	CRKL Amplification	Associated With EGFR-TKI Resistance	neg	drug		EGFR tyrosine kinase inhibitor		Therapy	24939008, 22586683
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		MET	7q31.2	Amplification		4233	7q31.2	Gain	MET Amplification	Acquired Resistance To EGFR Inhibitors In EGFR-Mutant Tumors	neg	drug		EGFR inhibitors		Therapy	24348666, 26628860
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		FGFR1	8p11.22	Amplification		2260	8p11.22	Gain	FGFR1 Amplification	Inhibited By Ponatinib Treatment	pos	drug	Ponatinib			Therapy	23563700
Squamous Cell Lung Cancer	Lung Neoplasms	D008175		MYC	8q24.21		Overexpression	4609	8q24.21	Gain	MYC overexpression	Benefit From FGFR Inhibitor Therapy With Concomitant FGFR1 Amplification	pos	drug	FGFR inhibitor			Therapy	24302556
Squamous Cell Lung Cancer	Lung Neoplasms	D008175		FGFR1	8p11.22	8p11.22 Amplification	Amplification	2260	8p11.22	Gain	FGFR1 Amplification	Benefit From FGFR Inhibitor Therapy With Concomitant MYC Overexpression	pos	drug	FGFR inhibitor			Therapy	24302556
Ovarian	Ovarian Neoplasms	D010051		CCNE1	19q12	Amplification		898	19q12	Gain	CCNE1 Amplification	Targeted Therapies May Be Available (i.e. CDK2 Inhibitors)	pos		CDK2 inhibitor			Therapy	23289505, 26204491, 25633797, 25892415
Ovarian	Ovarian Neoplasms	D010051		ERBB2	17q12	Amplification		2064	17q12	Gain	HER2 Amplification	Targeted Therapies May Be Available (i.e. HER2 Inhibitors)	pos		HER2 inhibitor			Therapy	25674538
Ovarian	Ovarian Neoplasms	D010051		KRAS	12p12.1	Amplification		3845	12p12.1	Gain	KRAS Amplification	Targeted Therapies May Be Available (i.e. RAS Inhibitors)	pos		RAS inhibitor			Therapy	23289505, 26691679
Ovarian	Ovarian Neoplasms	D010051		BRCA1	17q21.31	Deletion		672	17q21.31	Loss	BRCA1 Deletion	Targeted Therapies May Be Available (i.e.PARP Inhibitors)	pos		PARP inhibitors			Therapy	24225019, 26483957
Ovarian	Ovarian Neoplasms	D010051		BRCA2	13q13.1	Deletion		675	13q13.1	Loss	BRCA2 Deletion	Targeted Therapies May Be Available (i.e. PARP Inhibitors)	pos		PARP inhibitors			Therapy	24225019, 26483957
Ovarian	Ovarian Neoplasms	D010051		PTEN	10q23.31	Bi-allelic deletion		5728	10q23.31	Loss	PTEN Bi-allelic deletion	Targeted Therapies May Be Available (i.e. PI3K Pathway Inhibitors)	pos		PI3K pathway inhibitors			Therapy	24387334, 23289505, 25533673
Myelodysplastic Syndrome	Myelodysplastic Syndromes	D009190				5q deletion			5q	Loss	5q deletion	Targeted Therapies May Be Available (i.e. Lenalidomide)	pos	drug	Lenalidomide			Therapy	22488943
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				1p36.13 amplification			1p36.13	Gain	1p36.13 amplification	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				1p42.3 amplification			1p42.3	Gain	1p42.3 amplification	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				3p21.31 amplification			3p21.31	Gain	3p21.31 amplification	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				7q11.23 amplification			7q11.23	Gain	7q11.23 amplification	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				16p13.3 amplification			16p13.3	Gain	16p13.3 amplification	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				9p21.3 loss			9p21.3	Loss	9p21.3 loss	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				14q11.2 loss			14q11.2 loss	Loss	14q11.2 loss	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403		CDKN2A	9p21.3	Loss		1029	9p21.3	Loss	CDKN2A/B Loss	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403		CDKN2B	9p21.3	Loss		1030	9p21.3	Loss	CDKN2A/B Loss	Associated With Chemoresistance	neg	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				1p36.11 gain			1p36.11	Gain	1p36.11 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				1p36.22 gain			1p36.22	Gain	1p36.22 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				2q11.2 gain			2q11.2	Gain	2q11.2 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				8q24.3 gain			8q24.3	Gain	8q24.3 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				12p13.33 gain			12p13.33	Gain	12p13.33 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				22q13.2 gain			22q13.2	Gain	22q13.2 gain	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Diffuse Large B-Cell Lymphoma	Lymphoma, Large B-Cell, Diffuse	D016403				6p21.32 loss			6p21.32	Loss	6p21.32 loss	Associated With Chemo-Sensitive	pos	chemotherapy		Chemotherapy		Therapy	21504712
Mantle Cell Lymphoma	Lymphoma, Mantle-Cell	D020522		MDM2	12q15	Amplification		4193	12q15	Gain	MDM2 Amplification	Target For Nutlin-3 Therapy (MDM2 Antagonist; Activate TP53)	pos	drug	Nutlin-3			Therapy	23303139, 25439588, 25201201
Breast Cancer	Breast Neoplasms	D001943		ERBB2	17q12	Amplification	Increased expression	2064	17q12	Gain	ERBB2 Amplification	Targeted Therapies May Be Available (i.e. ERBB2 Inhibitor (HER2))	pos	drug		ERBB2 inhibitor (HER2)		Therapy	24470511, 24921704, 25674538, 26557900, 26635612
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		KIT	4q12	Amplification	Increased expression	3815	4q12	Gain	KIT Amplification	Targeted Therapies May Be Available (i.e. KIT Inhibitor)	pos	drug		KIT inhibitor		Therapy	24190702
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		PDGFRB	5q32	Amplification	Increased expression	5159	5q32	Gain	PDGFRB Amplification	Targeted Therapies May Be Available (i.e. PDGFRB Inhibitor)	pos	drug		PDGFRB inhibitor		Therapy	24359404, 24872713
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		FLT1	13q12.3	Amplification	Increased expression		13q12.3	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor)	pos	drug		VEGFR 1/2/3 inhibitor		Therapy	24243495, 25482937, 25773809
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		KDR	4q12	Amplification	Increased expression		4q12	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor)	pos	drug		VEGFR 1/2/3 inhibitor		Therapy	24243495, 26309897
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		FLT4	5q35.3	Amplification	Increased expression		5q35.3	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR 1/2/3 Inhibitor)	pos	drug		VEGFR 1/2/3 inhibitor		Therapy	24243495
Colorectal Cancer	Colorectal Neoplasms	D015179		VEGFA	6p21.1	Amplification	Increased expression		6p21.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24355210
Colorectal Cancer	Colorectal Neoplasms	D015179		VEGFB	11q13.1	Amplification	Increased expression		11q13.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24355210
Glioblastoma	Glioblastoma	D005909		VEGFA	6p21.1	Amplification	Increased expression		6p21.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24076268
Glioblastoma	Glioblastoma	D005909		VEGFB	11q13.1	Amplification	Increased expression		11q13.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24076268
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		VEGFA	6p21.1	Amplification	Increased expression		6p21.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24076268
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		VEGFB	11q13.1	Amplification	Increased expression		11q13.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24076268
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		VEGFA	6p21.1	Amplification	Increased expression		6p21.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24243495
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		VEGFB	11q13.1	Amplification	Increased expression		11q13.1	Gain	VEGF Amplification	Targeted Therapies May Be Available (i.e. VEGF Inhibitor)	pos	drug		VEGF inhibitor		Therapy	24243495
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		FLT3	13q12.2	Amplification	Increased expression	2322	13q12.2	Gain	FLT3 Amplification	Targeted Therapies May Be Available (i.e. FLT3 Inhibitor)	pos	drug		FLT3 inhibitor		Therapy	24756790, 26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		KIT	4q12	Amplification	Increased expression	3815	4q12	Gain	KIT Amplification	Targeted Therapies May Be Available (i.e. KIT Inhibitor)	pos	drug		KIT inhibitor		Therapy	26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		MET	7q31.2	Amplification	Increased expression	4233	7q31.2	Gain	MET Amplification	Targeted Therapies May Be Available (i.e. MET Inhibitor)	pos	drug		MET inhibitor		Therapy	24266843, 26628860, 26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		RET	10q11.21	Amplification	Increased expression	5979	10q11.21	Gain	RET Amplification	Targeted Therapies May Be Available (i.e. RET Inhibitor)	pos	drug		RET inhibitor		Therapy	26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		FLT1	13q12.3	Amplification	Increased expression		13q12.3	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR Inhibitor)	pos	drug		VEGFR inhibitor		Therapy	25482937, 25773809, 26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		KDR	4q12	Amplification	Increased expression		4q12	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR Inhibitor)	pos	drug		VEGFR inhibitor		Therapy	25773809, 26635725
Medullary Thyroid Cancer	Thyroid Neoplasms	D013964		FLT4	5q35.3	Amplification	Increased expression		5q35.3	Gain	VEGFR Amplification	Targeted Therapies May Be Available (i.e. VEGFR Inhibitor)	pos	drug		VEGFR inhibitor		Therapy	26635725
Colorectal Cancer	Colorectal Neoplasms	D015179		EGFR	7p11.2	Amplification	Increased expression	1956	7p11.2	Gain	EGFR Amplification	Targeted Therapies May Be Available (i.e. EGFR Inhibitor)	pos	drug		EGFR inhibitor		Therapy	24472471, 25110867
Squamous Cell Cancer Of Head And Neck	Head and Neck Neoplasms	D006258		EGFR	7p11.2	Amplification	Increased expression	1956	7p11.2	Gain	EGFR Amplification	Targeted Therapies May Be Available (i.e. EGFR Inhibitor)	pos	drug		EGFR inhibitor		Therapy	24412287, 25110867
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		ALK	2p23.1	Amplification	Increased expression	238	2p23.1	Gain	ALK Amplification	Targeted Therapies May Be Available (i.e. ALK Inhibitor)	pos	drug		ALK inhibitor		Therapy	26468446, 25806340
Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	D002289		MET	7q31.2	Amplification	Increased expression	4233	7q31.2	Gain	MET Amplification	Targeted Therapies May Be Available (i.e. MET Inhibitor)	pos	drug		MET inhibitor		Therapy	24355409, 25992382
Pancreatic Cancer	Pancreatic Neoplasms	D010190		EGFR	7p11.2	Amplification	Increased expression	1956	7p11.2	Gain	EGFR Amplification	Targeted Therapies May Be Available (i.e. EGFR Inhibitor)	pos	drug		EGFR inhibitor		Therapy	24432033, 25110867
Pancreatic Neuroendocrine Tumor	Pancreatic Neoplasms	D010190		MTOR	1p36.22	Amplification	Increased expression	2475	1p36.22	Gain	mTOR Amplification	Targeted Therapies May Be Available (i.e. mTOR Inhibitor)	pos	drug		mTOR inhibitor		Therapy	24333502
Renal Cell Carcinoma	Carcinoma, Renal Cell	D002292		MTOR	1p36.22	Amplification	Increased expression	2475	1p36.22	Gain	mTOR Amplification	Targeted Therapies May Be Available (i.e. mTOR Inhibitor)	pos	drug		mTOR inhibitor		Therapy	26309897, 24333502
Gastrointestinal Stromal Tumors	Gastrointestinal Stromal Tumors	D046152		KIT	4q12	Amplification	Increased expression	3815	4q12	Gain	KIT Amplification	Targeted Therapies May Be Available (i.e. KIT Inhibitor)	pos	drug		KIT inhibitor		Therapy	24384849
Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma	D018223		PDGFRA	4q12	Amplification	Increased expression		4q12	Gain	PDGFR Amplification	Targeted Therapies May Be Available (i.e. PDGFR Inhibitor)	pos	drug		PDGFR inhibitor		Therapy	24359404, 24872713
Dermatofibrosarcoma Protuberans	Dermatofibrosarcoma	D018223		PDGFRB	5q32	Amplification	Increased expression		5q32	Gain	PDGFR Amplification	Targeted Therapies May Be Available (i.e. PDGFR Inhibitor)	pos	drug		PDGFR inhibitor		Therapy	24359404, 24872713